- Home
- PTGX vs CUBI Comparison
PTGX vs CUBI Comparison
Compare PTGX & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- CUBI
- Stock Information
- Founded
- PTGX 2006
- CUBI 1994
- Country
- PTGX United States
- CUBI United States
- Employees
- PTGX N/A
- CUBI N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- CUBI Major Banks
- Sector
- PTGX Health Care
- CUBI Finance
- Exchange
- PTGX Nasdaq
- CUBI Nasdaq
- Market Cap
- PTGX 3.3B
- CUBI 1.7B
- IPO Year
- PTGX 2016
- CUBI 2012
- Fundamental
- Price
- PTGX $51.25
- CUBI $65.95
- Analyst Decision
- PTGX Strong Buy
- CUBI Buy
- Analyst Count
- PTGX 9
- CUBI 10
- Target Price
- PTGX $67.11
- CUBI $65.67
- AVG Volume (30 Days)
- PTGX 1.0M
- CUBI 323.6K
- Earning Date
- PTGX 08-05-2025
- CUBI 07-24-2025
- Dividend Yield
- PTGX N/A
- CUBI N/A
- EPS Growth
- PTGX N/A
- CUBI N/A
- EPS
- PTGX 0.86
- CUBI 3.98
- Revenue
- PTGX $207,801,000.00
- CUBI $591,500,000.00
- Revenue This Year
- PTGX N/A
- CUBI $12.34
- Revenue Next Year
- PTGX $47.15
- CUBI $10.08
- P/E Ratio
- PTGX $59.19
- CUBI $16.56
- Revenue Growth
- PTGX N/A
- CUBI N/A
- 52 Week Low
- PTGX $32.50
- CUBI $40.75
- 52 Week High
- PTGX $60.60
- CUBI $68.49
- Technical
- Relative Strength Index (RSI)
- PTGX 45.80
- CUBI 83.74
- Support Level
- PTGX $49.86
- CUBI $58.52
- Resistance Level
- PTGX $57.24
- CUBI $51.55
- Average True Range (ATR)
- PTGX 2.06
- CUBI 1.84
- MACD
- PTGX -0.78
- CUBI 1.29
- Stochastic Oscillator
- PTGX 16.14
- CUBI 92.76
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.